A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
Gabexate has been studied across 20 research domains including 🔬 Oncology, 🔬 Inflammation, ❤️ Cardiovascular, 🫁 Liver & Detox, 🛡️ Immunity. The primary research focus is 🔬 Oncology with 19% of studies addressing this area.
The following compounds share molecular targets with Gabexate, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Gabexate is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.